皮肤进展期黑色素瘤的瘤体内治疗进展

Research progress of intralesional injection for advanced skin melanoma

瘤体内注射指向肿瘤局部病灶内注射抗肿瘤药物,在杀灭注射部位肿瘤细胞的同时,并可能引发免疫反应,产生"旁观者"效应,对非注射病灶也发挥抗肿瘤作用。2015年10月美国食品和药物管理局审批通过黑色素瘤瘤体内注射治疗的新型药物Talimogene laherparepvec上市,用于首次手术后复发的黑色素瘤患者不可切除的皮肤、皮下和淋巴结病灶的局部治疗,引发人们对该治疗手段的极大关注。本文对以往用于皮肤进展期黑色素瘤瘤体内注射治疗的药物及其相关疗效进行综述,其中包括细胞因子、质粒及溶瘤病毒等,并对该类型药物的进一步发展提出展望。

Intralesional injection is an anti-tumor therapy in which the injected agents shrink the tumor directly and stimulate a systemic immune response to kill non-injected tumors（ namely bystander effect）. Talimogene laherparepvec,an intralesional injection agent,was approved by U.S. Food and Drug Administration on October,2015 for the local treatment of unresectable cutaneous,subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery,inspiring more attention to this treatment method. In the current review,we summarize a series of intralesional injection agents（ including cytokines,plasmid,oncolytic virus,etc.） for melanoma and propose future study in this field.